Real-World data sought on nivolumab for bladder cancer after surgery
NCT ID NCT05779592
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study observes 400 Japanese patients with muscle-invasive urothelial carcinoma who received nivolumab after surgery to remove their cancer. Researchers will track how long patients stay cancer-free, side effects, and how the drug is actually used in clinics. The goal is to see if nivolumab's benefits seen in clinical trials hold up in everyday practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab
- What this could lead to
- If successful, this study could confirm that nivolumab is effective and safe in everyday clinical settings for preventing cancer recurrence after surgery.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. It only includes Japanese patients, so findings may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Local Institution
City, State, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study aims to uncover nerve side effects of cancer drug
- New drug cocktail aims to control bladder cancer before surgery
- New combo therapy aims to stop bladder cancer return after surgery
- Immunotherapy combo shows promise for bladder cancer patients unable to get chemo
- Personalized vaccine + immunotherapy aims to stop bladder cancer return